Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen - PubMed (original) (raw)

Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen

Ming Chen et al. Oncol Lett. 2013 Jul.

Abstract

The aim of the present study was to explore the correlation between estrogen receptor α (ERα) phosphorylation at serines 118 and 167 and the responsiveness of patients with primary breast cancer to tamoxifen. Tumors from 104 patients with primary breast cancer who received adjuvant tamoxifen therapy at The Affiliated Cancer Hospital of Shantou University Medical College between January 2001 to December 2007 were subjected to immunohistochemical analysis with specific antibodies against ERα phosphorylated at either serine 118 (pERα-S118) and/or serine 167 (pERα-S167). ERα phosphorylation at the two sites was correlated with either the disease-free survival or the overall survival rate of these patients using the Kaplan-Meier survival analysis. pERα-S118 and pERα-S167 were found to be expressed in the cell nucleus of 25.0% (26/104) and 26.9% (28/104) of breast cancers, respectively. The expression of pERα-S118 was positively correlated with the human epidermal growth factor receptor-2 (HER-2) status (χ2=6.85, P=0.01). The Kaplan-Meier analysis revealed a poorer disease-free (P=0.022) and overall survival (P=0.013) in breast cancer patients expressing pERα-S118, but not in those expressing pERα-S167. In conclusion, pERα-S118 was correlated with the HER-2 status and predicted breast cancer resistance to tamoxifen.

Keywords: breast cancer; endocrine resistance; estrogen receptor α; phosphorylation; tamoxifen.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Immunohistochemical results of estrogen receptor α phosphorylation at serine 118 (pERα-S118) and 167 (pERα-S167) in patients with primary breast cancer. (A) pERα-S118 (+); (B) pERα-S118 (+++); (C) pERα-S118 (−); (D) pERα-S167 (+); (E) pERα-S167 (+++); and (F) pERα-S167 (−). Magnification, x200. −, negative; +, weakly positive; +++, strongly positive.

Figure 2.

Figure 2.

Kaplan-Meier graphs for the disease-free and overall survival rates of 104 primary breast cancer patients undergoing tamoxifen therapy.

Figure 3.

Figure 3.

Kaplan-Meier graphs for the effect of the phosphorylation of estrogen receptor α at serine 118 (pERα-S118) and 167 (pERα-S167) on (A,C) disease-free and (B,D) overall survival. (A) χ2=5.218 and P=0.022; (B) χ2=6.216 and P=0.013; (C) χ2=0.424 and P=0.515; and (D) χ2=1.075 and P=0.300.

Similar articles

Cited by

References

    1. Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) 2012;26:688–694. 696. - PubMed
    1. Murphy LC, Seekallu SV, Watson PH. Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer. 2011;18:R1–R14. - PubMed
    1. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol. 2011;25:516–528. - PMC - PubMed
    1. de Leeuw R, Neefjes J, Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer. 2011;2011:232435. - PMC - PubMed
    1. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer. 2007;7:713–722. - PubMed

LinkOut - more resources